Tilray Medical

Tilray Medical regards the recent classification by the KBV and the GKV-Spitzenverband on prescribing full‑spectrum extracts in standardized quality as an important step forward for clinical practice and patient access. The company is calling for a legal clarification to ensure long‑term legal certainty for doctors, patients, providers and payers and to make therapy and reimbursement pathways predictable. Tilray emphasizes the importance of freedom of therapy, continuity of care and broad access to high‑quality cannabis medicines, and offers its production and supply infrastructure to support the transition. Tilray holds around a 45 percent market share in Germany for medical cannabis extracts and says it is able to help shape further development of the supply framework. » Más en finanzen.net

Tilray Medical Deutschland has announced the launch of ARX, a locally developed premium brand for medical cannabis grown at the Aphria RX facility in Neumünster to EU‑GMP standards. ARX is based on strains from Broken Coast’s gene bank and combines Canadian breeding know‑how with German production and national distribution via CC Pharma and 14U Pharma. The brand will be presented at Mary Jane Berlin 2026 and aims to deliver greater consistency, supply security and long‑term access for patients and healthcare professionals. » Más en finanzen.net

Tilray Medical is consolidating its Italian activities under Tilray Medical Italia to strengthen its market presence in one of the most important regulated European markets. The company offers a growing range of medical cannabis products (flowers and oils) approved by the Italian Ministry of Health, which are EU‑GMP certified and distributed through hospitals and pharmacies. Tilray is working in Italy with Molteni Farmaceutici to ensure supply, physician training, and quality, safety and regulatory compliance. The move is part of Tilray's Europe‑wide strategy to unify medical cannabis activities under a global medical brand. » Más en finanzen.net